超敏动态全身[18F]FDG PET/CT得出的Patlak-Ki与局部晚期非小细胞肺癌患者诱导免疫化疗反应相关
本研究纳入37例接受两周期诱导免疫化疗的局部晚期非小细胞肺癌患者,治疗前进行60分钟动态全身[18F]FDG PET/CT,以Patlak-Ki等代谢特征预测反应。Patlak-Ki的K-Means决策边界为2.779 ml/min/100 g,高Patlak-Ki组客观缓解率87%(20/23)高于低Patlak-Ki组35.7%(5/14)(P=0.001),Patlak-Ki预测反应的灵敏度80%、特异度75%[AUC=0.775(95%CI 0.605-0.945)]。
要点
- 37例局部晚期非小细胞肺癌患者中,高Patlak-Ki组客观缓解率为87%(20/23),低Patlak-Ki组为35.7%(5/14)(P=0.001)。
- Patlak-Ki预测诱导免疫化疗反应的灵敏度80%、特异度75%[AUC=0.775(95%CI 0.605-0.945)]。
- 高Patlak-Ki组原发肿瘤中CD3+/CD8+ T细胞及CD86+/CD163+/CD206+巨噬细胞表达更高。
核心结论
- 全身[18F]FDG PET/CT动态采集可依据Patlak-Ki将局部晚期非小细胞肺癌患者分为高Patlak-Ki组与低Patlak-Ki组;高Patlak-Ki组对诱导免疫化疗反应更好,原发肿瘤免疫细胞浸润水平更高;需更大样本进一步研究验证这些发现。
研究设计与样本
- 分析2020年9月至2021年11月间37例接受两周期诱导免疫化疗的局部晚期非小细胞肺癌患者,治疗前完成60分钟动态全身[18F]FDG PET/CT扫描。
- 手动勾画原发肿瘤,评估Patlak-Ki、Patlak-Intercept、SUVmax、MTV和TLG等代谢特征,Patlak-Ki由20-60分钟帧经Patlak图形分析计算。
- 采用Laplacian特征重要性评分选择最佳特征,以无监督K-Means方法对患者聚类,用ROC曲线检验所选代谢特征预测治疗反应的效果。
- 对1021个基因行靶向下一代测序,并用免疫组化检测CD68、CD86、CD163、CD206、CD33、CD34、Ki67和VEGFA表达。
- 组间比较采用独立样本t检验和Mann-Whitney U检验,以P<0.05为统计学显著。
主要发现
- 全队列诱导免疫化疗的客观缓解率为67.6%(25/37),高Patlak-Ki组为87%(20/23),低Patlak-Ki组为35.7%(5/14)(P=0.001)。
- Patlak-Ki预测治疗反应的灵敏度为80%、特异度为75%[AUC=0.775(95%CI 0.605-0.945)]。
- 高Patlak-Ki组原发肿瘤中CD3+/CD8+ T细胞及CD86+/CD163+/CD206+巨噬细胞表达高于低Patlak-Ki组。
- 两组间Ki67、CD33+髓系细胞、CD34+微血管密度(MVD)和肿瘤突变负荷(TMB)相当。
- Laplacian评分显示原发肿瘤Patlak-Ki对患者聚类的重要性最高,K-Means得出的Patlak-Ki决策边界为2.779 ml/min/100 g。
关键数值与推荐
- Patlak-Ki分组阈值为2.779 ml/min/100 g:Patlak-Ki>2.779 ml/min/100 g为高FDG Patlak-Ki组(n=23),Patlak-Ki≤2.779 ml/min/100 g为低FDG Patlak-Ki组(n=14)。
- 治疗反应按RECIST 1.1标准评估。
- 所有患者接受两周期诱导化疗联合Nivolumab/Camrelizumab。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需更大样本的患者队列进一步研究以验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to investigate the predictive value of metabolic features in response to induction immuno-chemotherapy in patients with locally advanced non-small cell cancer (LA-NSCLC), using ultra-high sensitivity dynamic total body [18F]FDG PET/CT. METHODS: The study analyzed LA-NSCLC patients who received two cycles of induction immuno-chemotherapy and underwent a 60-min dynamic total body [18F]FDG PET/CT scan before treatment. The primary tumors (PTs) were manually delineated, and their metabolic features, including the Patlak-Ki, Patlak-Intercept, maximum SUV (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were evaluated. The overall response rate (ORR) to induction immuno-chemotherapy was evaluated according to RECIST 1.1 criteria. The Patlak-Ki of PTs was calculated from the 20-60 min frames using the Patlak graphical analysis. The best feature was selected using Laplacian feature importance scores, and an unsupervised K-Means method was applied to cluster patients. ROC curve was used to examine the effect of selected metabolic feature in predicting tumor response to treatment. The targeted next generation sequencing on 1021 genes was conducted. The expressions of CD68, CD86, CD163, CD206, CD33, CD34, Ki67 and VEGFA were assayed through immunohistochemistry. The independent samples t test and the Mann-Whitney U test were applied in the intergroup comparison. Statistical significance was considered at P < 0.05. RESULTS: Thirty-seven LA-NSCLC patients were analyzed between September 2020 and November 2021. All patients received two cycles of induction chemotherapy combined with Nivolumab/ Camrelizumab. The Laplacian scores showed that the Patlak-Ki of PTs had the highest importance for patient clustering, and the unsupervised K-Means derived decision boundary of Patlak-Ki was 2.779 ml/min/100 g. Patients were categorized into two groups based on their Patlak-Ki values: high FDG Patlak-Ki (H-FDG-Ki, Patlak-Ki > 2.779 ml/min/100 g) group (n = 23) and low FDG Patlak-Ki (L-FDG-Ki, Patlak-Ki ≤ 2.779 ml/min/100 g) group (n = 14). The ORR to induction immuno-chemotherapy was 67.6% (25/37) in the whole cohort, with 87% (20/23) in H-FDG-Ki group and 35.7% (5/14) in L-FDG-Ki group (P = 0.001). The sensitivity and specificity of Patlak-Ki in predicting the treatment response were 80% and 75%, respectively [AUC = 0.775 (95%CI 0.605-0.945)]. The expression of CD3+/CD8+ T cells and CD86+/CD163+/CD206+ macrophages were higher in the H-FDG-Ki group, while Ki67, CD33+ myeloid cells, CD34+ micro-vessel density (MVD) and tumor mutation burden (TMB) were comparable between the two groups. CONCLUSIONS: The total body [18F]FDG PET/CT scanner performed a dynamic acquisition of the entire body and clustered LA-NSCLC patients into H-FDG-Ki and L-FDG-Ki groups based on the Patlak-Ki. Patients with H-FDG-Ki demonstrated better response to induction immuno-chemotherapy and higher levels of immune cell infiltration in the PTs compared to those with L-FDG-Ki. Further studies with a larger patient cohort are required to validate these findings.
引用
- Wang D, Qiu B, Liu Q, et al. Patlak-Ki derived from ultra-high sensitivity dynamic total body [18F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2023. PMID: 37310427. doi:10.1007/s00259-023-06298-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。